Loading
A phase 3 trial of Camizestrant, Tamoxifen and Exemestane in advanced solid tumours, run by AstraZeneca, now recruiting.
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy is a phase 3 interventional study registered as NCT05774951 by AstraZeneca, with 4300 participants planned, started 2023-03-31 and due to reach its primary completion in 2027-04-20. Interventions recorded: Camizestrant, Tamoxifen, Anastrozole, Letrozole and Exemestane.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/